Proficio Capital Partners LLC Invests $941,000 in Illumina, Inc. $ILMN

Proficio Capital Partners LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,353 shares of the life sciences company’s stock, valued at approximately $941,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Fiduciary Financial Advisors purchased a new stake in Illumina in the 2nd quarter valued at $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the second quarter valued at approximately $32,000. Rakuten Securities Inc. acquired a new stake in shares of Illumina in the second quarter valued at $33,000. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the fourth quarter worth approximately $25,000. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ILMN. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Canaccord Genuity Group increased their price objective on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reissued an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Guggenheim increased their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Stock Performance

Shares of ILMN opened at $224.84 on Thursday. The company’s fifty day moving average is $191.66 and its 200-day moving average is $154.42. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $227.70. The firm has a market cap of $33.95 billion, a price-to-earnings ratio of 41.95, a price-to-earnings-growth ratio of 3.17 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,874,458 shares of company stock worth $367,996,424 in the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.